Page last checked
GLP-1/glucagon dual receptor agonist · dosing
The published trial tested 4–6 mg once weekly, stepped up from 2 mg in four-week stages. It enrolled 610 participants and ran as the 48-week phase 3 obesity trial. Mazdutide has no FDA-approved dosing label. One later readout studied 9 mg targets; each result shows its publication status, and missing dose steps stay unreported. Those are randomized study regimens, not a schedule for personal use.
Source: Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736)
These peer-reviewed results were published after the primary dosing study below. Each study stays separate so its population, regimen and outcome remain attached to the source that reported them.
| Target | Dose path | Mean weight change · week 60 | Publication status |
|---|---|---|---|
| 9 mg weekly | Intermediate steps not reported | 16.65% decrease | Peer-reviewed trial result |
| Placebo | — | 1.5% decrease | Peer-reviewed trial result |
The registry records 462 randomized participants. The paper’s efficacy and safety analysis included 461 people who received at least one dose: 307 on mazdutide and 154 on placebo. Registry: NCT06164873. Sources retrieved 2026-08-17.
These are the once-weekly dose groups used in the published trial. The table prints only the dose detail the source supplies. They describe a randomized protocol under monitoring, not a recommended titration schedule.
| Arm | Once-weekly dose | Position in the studied range | How the trial reached it |
|---|---|---|---|
| 1 | 4 mg | Lowest arm studied | 2 mg weekly for 4 weeks, then 4 mg weekly for 44 weeks. One step, held four weeks, then the rest of the year at the target. This is the lower of the two arms, the shorter climb, and the one that reached its dose soonest |
| 2 | 6 mg | Highest arm studied | 2 mg for 4 weeks, then 4 mg for 4 weeks, then 6 mg weekly for 40 weeks. Two months of lower doses before this arm’s own dose begins, which is a sixth of the trial spent under the amount the arm is named for |
Source: Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736) · retrieved 2026-08-17 · the paths above reproduce only the doses the source names. The source does not turn those paths into advice.
| Target-dose group | Mean change at 48 weeks | How the paper reports it |
|---|---|---|
| 4 mg weekly | 11% decrease | 2 mg weekly for 4 weeks, then 4 mg weekly for 44 weeks. One step, held four weeks, then the rest of the year at the target. This is the lower of the two arms, the shorter climb, and the one that reached its dose soonest |
| 6 mg weekly | 14.01% decrease | 2 mg for 4 weeks, then 4 mg for 4 weeks, then 6 mg weekly for 40 weeks. Two months of lower doses before this arm’s own dose begins, which is a sixth of the trial spent under the amount the arm is named for |
| Placebo | 0.3% decrease | Placebo group |
Source: Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736) · retrieved 2026-08-17. Only outcomes the cited paper reports for a named arm appear here; no missing result is estimated.
A dosage chart is a regulatory artifact before it is an editorial one. It exists when an agency has reviewed a sponsor’s trials, agreed a schedule, and bound the manufacturer to a product of stated identity and potency. Mazdutide has none of that yet.
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.
This is the one compound on this site approved somewhere and not here.
China approved mazdutide in June 2025 for weight, and in September 2025 for type 2 diabetes. It is sold there as Xinermei. That approval governs a Chinese pharmacy and nothing else.
FDA has approved no mazdutide product, and a Drugs@FDA search on 13 August 2026 found nothing under any of its four names. The drug is dispensed under supervision several thousand miles away. Anything reaching a US reader outside that is unapproved and unchecked.
No schedule is copied from the Chinese label, because nobody here has read it.
Sites that publish a titration chart for a compound at this stage have built it by inference. They take a trial’s target dose and reverse-engineer a plausible ramp toward it. The result looks exactly like a supported schedule and should not be read as one. The table shows only the trial arms that were actually studied.
The table above answers one narrow question: what the completed injection study tested. It does not join separate formulations or unfinished trials into a single path. Three boundaries remain attached to the record:
A unit is not a unit. A U-100 and a U-50 barrel both print 0.01 mL per graduation; a U-40 barrel prints 0.025 mL. The same printed number therefore measures 2.5× the volume on a U-40. That is why every unit figure on this page names its barrel. It is also why a unit count copied from someone else’s syringe means nothing on its own.
| Barrel | Capacity | One graduation | 0.5 mL reads as |
|---|---|---|---|
| U-100 insulin syringe · 1 mL · lines every 2 units | 1 mL | 0.010 mL | 50 units |
| U-100 insulin syringe · 0.5 mL · lines every 1 unit | 0.5 mL | 0.010 mL | 50 units |
| U-40 insulin syringe · 1 mL · lines every 1 unit | 1 mL | 0.025 mL | 20 units |
Barrel capacities and graduation spacing are the printed scales this site’s calculator measures against, not estimates. Three barrels carry only two scales: a U-50 is a half-length U-100, so it reads identically per unit and simply runs out sooner.
Reconstitution fixes a concentration, and the concentration fixes what a single graduation carries — before anyone decides what to draw. Below is every pairing of this page’s vial sizes and water volumes, as a concentration and as the mass one U-100 graduation holds at it. No dose is implied by any cell; it is division.
| Vial | + 1 mL water | + 2 mL water |
|---|---|---|
| 10 mg | 10 mg/mL100 mcg per unit | 5 mg/mL50 mcg per unit |
Vial strengths and water volumes are the Mazdutide record’s own presets. One U-100 graduation is 0.01 mL, so the mass it carries is the concentration times that volume. That is the entire reason the same milligram figure produces a different unit count in every row.
The dose climbs in steps for one reason: how well people tolerate it, not how well it works. The receptors that produce the effect you want are the same ones that slow your stomach down, and your gut reacts hardest when the exposure is new. Hold it steady and the reaction fades. Stepping up gradually is a way of using that — each step is a stretch of time for your body to settle at where it is before the next increase arrives.
The length of each step matters. Shortening it moves the next increase into a period when the body may not have adjusted. Labels and trial plans state the intervals that were tested. A faster ramp was not tested.
A dose-finding trial is an experiment about doses, not a recommendation of one. Its arms exist to spread people across a range so researchers can see the shape of the curve. Some arms are set deliberately low, where too little effect is expected. Others are set high, where people are expected to struggle. Reading the top arm as the target gets the design backwards: the reason for running the whole range was that nobody yet knew which part of it was right.
Trial doses came with screening, monitoring, a set schedule and drug of tested strength and purity. Removing a milligram figure from those conditions removes much of what made it meaningful. The table therefore shows what researchers tested, not a schedule to follow.
The dose and the syringe draw are two different things. The dose is a mass in milligrams. The draw is a volume in syringe units. It depends on the concentration after mixing. Adding more bacteriostatic water changes the unit reading, but not the dose.
This matters because a unit count copied from someone else’s vial means nothing without their concentration. That mismatch is the most common way a self-injected dose ends up ten times off. The arithmetic is fixed and safe to state as fact. The dose you apply it to is a clinical decision, and it is not.
No approved Mazdutide product exists, so nothing here describes one. The calculator does arithmetic only: it converts a milligram figure and a reconstitution into a volume and a unit count, and it takes no position on which figure belongs in the box.
Open the Mazdutide calculator →The later trial studied 9 mg weekly. Where the public sources do not name the intermediate steps, the table says so instead of reconstructing them. These are monitored trial protocols, not an approved schedule.
Yes. Every later result shown here is peer reviewed, and its registry record remains linked separately so study identity and publication evidence do not collapse into one source.
The trial ran 2 once-weekly regimens between 4 mg and 6 mg for 48 weeks. An arm is a group a protocol assigned, not a dosage anybody settled on. These are study regimens, not an approved dosing schedule.
The trial ran as a 48-week phase 3 obesity trial. The page’s own description is once weekly, stepped up from 2 mg in four-week stages. Nothing published here establishes what a faster ramp would produce.
The next increase is optional, not automatic. The label allows a longer stay at the current step when needed. A clinician decides what happens after a dose is hard to handle; the schedule alone cannot make that decision.
Yes. One randomized group received 4 mg once weekly for 48 weeks and the group changed by an average of -11% by week 48. That proves the dose was studied; it does not make it an approved starting dose or a recommendation.
The highest arm studied was 6 mg once weekly. It is simply the highest amount the trial tested. It is not a maximum dose, because no regulator has set one.
No. The dose is a mass in milligrams and comes from the source; the draw is a volume in syringe units and comes from dividing that mass by the concentration reconstitution produced. Adding more bacteriostatic water to the same vial changes every unit figure and changes no dose at all. That is also why a unit count copied from someone else’s vial means nothing without their concentration.
Because a chart is a claim about provenance, not a formatting choice. Where an FDA-approved label specifies a schedule, this site quotes it row by row and cites the label under the table. Where no label exists, the guide shows what trials tested and says plainly that it is not a schedule. For Mazdutide, that is the 48-week phase 3 obesity trial above.